A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain.

Vinita SinghTheresa W GillespieOlabisi LaneBoris SpektorAli John ZarrabiKatherine EganKimberly CurseenMaya TsvetkovaJan H BeumerRoman SniecinskiJack W ShteamerJeffery SwitchenkoR Donald Harvey

Published in: Pharmacotherapy (2022)

In this single-institution study, all dosages of IN ketamine administered in the study (10, 30, and 50 mg) provided significant pain relief for intractable cancer-related pain and were well tolerated. The 50 mg dose provided maximal pain relief without major side effects. Further study focused on repeated administration efficacy and safety for cancer-related pain is warranted.

Keyphrases

chronic pain
pain management
neuropathic pain
clinical trial
randomized controlled trial
blood pressure
spinal cord injury
body composition
postoperative pain